Alnylam Submits Regulatory Application for Vutrisiran, Predicts Multibillion-Dollar Product with 60% Success Rate

Oct 17, 2024, 01:30 PM

Alnylam Pharmaceuticals has submitted a regulatory application to the European Medicines Agency for its drug Vutrisiran, aimed at treating ATTR amyloidosis with cardiomyopathy. The submission reflects the company's strategic focus on expanding its product offerings in the competitive biotech landscape. Alnylam's CEO, Yvonne Greenstreet, expressed confidence in the drug's potential, predicting it could become a multibillion-dollar product despite rising competition. At the recent STAT Summit, Greenstreet highlighted a 60% probability of success for their RNAi drug development programs, emphasizing the importance of providing quality therapeutic options to stimulate diagnosis rates for rare conditions. The company, co-founded by former CEO J. Maraganore, is positioned to be a leading player in the biotech sector.